Abcam Launches SimpleStep ELISA Kits
Abcam plc., a producer and distributor of high quality protein research tools, has launched a range of SimpleStep ELISA kits. The new kits have a greatly simplified protocol when compared with standard multi-step ELISAs, providing significant time savings and ease of use.
Offering enhanced performance, SimpleStep ELISA kits are single wash, colorimetric sandwich ELISAs that retain the familiar process and data outputs of a traditional ELISA kit. The kits require no specialised training or instrumentation and in contrast to standard ELISA achieve increased accuracy due to reduced sample handling steps. In addition, a more efficient in-solution binding process provides superior sensitivity and specificity.
The SimpleStep kits are ideal for studying intra- or extra- cellular signaling pathways or for cancer biomarker research. Numerous new kits are being added to the already extensive range each month. The kits are available in convenient off-the-shelf 1, 2, or 4 target conformation. Custom multi-target kits are also available, allowing customers to select analyte combinations specific to their research.
James Murray, General Manager, Abcam Eugene, commented: “Abcam is continually in touch with researchers to anticipate the latest research trends and developments, so that we can continue to meet their needs worldwide. We’re excited to see how SimpleStep ELISA kits will help to increase the pace of scientific discoveries.”
Developed and manufactured at Abcam’s laboratories, SimpleStep ELISAs have been extensively validated for specificity and sensitivity in a broad range of sample types and are accompanied by information-rich datasheets and expert scientific support. Addition of these kits enhances Abcam’s already extensive immunoassay portfolio consisting of 1600 products for the detection of more than 600 targets.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance